Indeed, talimogene laherparepvec (T-VEC), a recombinant herpes simplex virus 1 containing the GM-CSF (Granulocyte Macrophage colony-stimulating Factor) gene, combined with ipilimumab, an anti-CTLA4 antibody, demonstrated greater anti-tumor activity compared to ipilimumab alone in patients with advanced melanoma10. This evidence concerns the gene CSF2 and neoplasm.